Impact of body mass index (BMI) on outcome in 785 patients (pts) receiving systemic chemotherapy (CT) and bevacizumab (BEV) for primary advanced ovarian cancer (OC). 15. Januar 2018 Sehouli, J., Mustea, A., Oskay-Özcelik, G., Gabowski, G., Keller, M., Richter, R., Harde, J., Klawitter, S., Wegenaer, A., Tomé, O., Wimberger, P., 2017. Ann Oncol 28 (Supplement 5)(958P), 341. doi:10.1093/annonc/mdx372 Abstract Overall survival and patient-reported impairment by fatigue, pain and treatment time in patients with advanced breast cancer in routine practice – results from the prospective German TMK cohort study. N Marschner, T Fietz, J Rauh, A Nusch, U Söling, M Frank, L Kruggel, M Jänicke, 2017. The Breast, Volume 36, S45 https://doi.org/10.1016/S0960-9776(17)30688-4… Weiterlesen Influence of comorbidities on clinical outcome in patients (pts) receiving chemotherapy (CT) + bevacizumab (BEV) for primary advanced ovarian cancer (OC). Woopen, H., Wimberger, P., Mustea, A., Oskay-Oezcelik, G., Keller, M., Richter, R., Harde, J., Klawitter, S., Wegenaer, A., Tomé, O., Sehouli, J., 2017. Ann Oncol… Weiterlesen